Skip to main content
Top
Published in: Diabetologia 2/2006

01-02-2006 | Article

Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus

Authors: R. de Vries, G. M. Dallinga-Thie, A. J. Smit, B. H. R. Wolffenbuttel, A. van Tol, R. P. F. Dullaart

Published in: Diabetologia | Issue 2/2006

Login to get access

Abstract

Aim/hypothesis

The plasma activity of phospholipid transfer protein (PLTP), which has putative pro- and anti-atherogenic roles in lipoprotein metabolism, is increased in type 2 diabetes mellitus. We analysed the relationship between carotid artery intima–media thickness (IMT), an established marker of atherosclerosis, and PLTP activity in diabetic patients and control subjects.

Methods

The IMT (mean of three segments in both carotid arteries by ultrasonography), clinical variables, plasma PLTP activity (phospholipid vesicle–HDL system), lipoproteins, C-reactive protein and insulin were measured in 87 non-smoking men and women, who had type 2 diabetes mellitus, no cardiovascular disease, and were not on insulin or lipid-lowering medication, and in 83 age-matched control subjects.

Results

In diabetic patients, carotid IMT (p=0.02), pulse pressure (p=0.003), plasma PLTP activity (p<0.001), triglycerides (p=0.01), C-reactive protein (p<0.01) and insulin (p<0.001) were higher, whereas HDL cholesterol was lower (p<0.001) than in control subjects. Multiple stepwise linear regression analysis demonstrated that in type 2 diabetic patients IMT was independently associated with age (p<0.001), sex (p=0.001), pulse pressure (p=0.003), plasma PLTP activity (p=0.03) and HDL cholesterol (p=0.03), but not with very low density lipoprotein+LDL cholesterol, triglycerides, C-reactive protein and insulin (all p>0.20). The relationship between plasma PLTP activity and IMT was not significant in control subjects.

Conclusions/interpretation

Plasma PLTP activity is a positive determinant of IMT in type 2 diabetes mellitus, suggesting that high PLTP activity is involved in accelerated atherosclerosis in this disease.
Literature
1.
go back to reference Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ (1985) Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density proteins during lipolysis. J Lipid Res 26:842–851PubMed Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ (1985) Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density proteins during lipolysis. J Lipid Res 26:842–851PubMed
3.
go back to reference Jauhiainen M, Metso J, Pahlman R, Blomqvist S, Van Tol A, Ehnholm C (1993) Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268:4032–4036PubMed Jauhiainen M, Metso J, Pahlman R, Blomqvist S, Van Tol A, Ehnholm C (1993) Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268:4032–4036PubMed
4.
go back to reference Von Eckardstein A, Jauhiainen M, Huang Y et al (1996) Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre b1-HDL. Biochim Biophys Acta 1301:255–262 Von Eckardstein A, Jauhiainen M, Huang Y et al (1996) Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre b1-HDL. Biochim Biophys Acta 1301:255–262
5.
go back to reference Settasatian N, Duong M, Curtiss LK et al (2001) The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 276:26898–26905PubMedCrossRef Settasatian N, Duong M, Curtiss LK et al (2001) The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 276:26898–26905PubMedCrossRef
6.
go back to reference Jiang X, Francone OL, Bruce C et al (1996) Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 98:2373–2380PubMedCrossRef Jiang X, Francone OL, Bruce C et al (1996) Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 98:2373–2380PubMedCrossRef
7.
go back to reference Van Haperen R, Van Tol A, Vermeulen P et al (2000) Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082–1088PubMed Van Haperen R, Van Tol A, Vermeulen P et al (2000) Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082–1088PubMed
8.
go back to reference Lie J, De Crom R, Van Gent T et al (2002) Elevation of plasma phospholipid transfer protein in transgenic mice increases very low density lipoprotein secretion. J Lipid Res 43:1875–1880PubMedCrossRef Lie J, De Crom R, Van Gent T et al (2002) Elevation of plasma phospholipid transfer protein in transgenic mice increases very low density lipoprotein secretion. J Lipid Res 43:1875–1880PubMedCrossRef
9.
go back to reference Van Haperen R, Van Tol A, Van Gent T et al (2002) Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 277:48938–48943PubMedCrossRef Van Haperen R, Van Tol A, Van Gent T et al (2002) Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J Biol Chem 277:48938–48943PubMedCrossRef
10.
go back to reference Jiang XC, Qin S, Qiao C et al (2001) Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7:847–852PubMedCrossRef Jiang XC, Qin S, Qiao C et al (2001) Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7:847–852PubMedCrossRef
11.
go back to reference Jiang X, Tall AR, Qin S et al (2002) Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 277:31850–31856PubMedCrossRef Jiang X, Tall AR, Qin S et al (2002) Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 277:31850–31856PubMedCrossRef
12.
go back to reference Yang X, Yan D, Qiao C et al (2003) Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23:1601–1607PubMedCrossRef Yang X, Yan D, Qiao C et al (2003) Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23:1601–1607PubMedCrossRef
13.
go back to reference Schlitt A, Bickel C, Thumma P et al (2003) High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 23:1857–1862PubMedCrossRef Schlitt A, Bickel C, Thumma P et al (2003) High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 23:1857–1862PubMedCrossRef
14.
go back to reference Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188–194PubMed Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188–194PubMed
15.
go back to reference Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF (1998) Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese NIDDM patients. Diabetologia 41:929–934PubMedCrossRef Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF (1998) Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese NIDDM patients. Diabetologia 41:929–934PubMedCrossRef
16.
go back to reference Kaser S, Sandhofer A, Föger B et al (2001) Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 44:1111–1117PubMedCrossRef Kaser S, Sandhofer A, Föger B et al (2001) Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 44:1111–1117PubMedCrossRef
17.
go back to reference Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71–79PubMedCrossRef Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140:71–79PubMedCrossRef
18.
go back to reference Desrumaux C, Athias A, Bessède G et al (1999) Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 19:266–275PubMed Desrumaux C, Athias A, Bessède G et al (1999) Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 19:266–275PubMed
19.
go back to reference Tan KC, Shiu SW, Wong Y, Tam S (2005) Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 178:365–370PubMedCrossRef Tan KC, Shiu SW, Wong Y, Tam S (2005) Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 178:365–370PubMedCrossRef
20.
go back to reference De Groot E, Hovingh GK, Wiegman A et al (2004) Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 109 [23 Suppl 1]:III33–III38PubMed De Groot E, Hovingh GK, Wiegman A et al (2004) Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 109 [23 Suppl 1]:III33–III38PubMed
21.
go back to reference Selzer RH, Hodis HN, Kwong-Fu H et al (1994) Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 111:1–11PubMedCrossRef Selzer RH, Hodis HN, Kwong-Fu H et al (1994) Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images. Atherosclerosis 111:1–11PubMedCrossRef
22.
go back to reference Speijer H, Groener JE, Van Ramshorst E, Van Tol A (1991) Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90:159–168PubMedCrossRef Speijer H, Groener JE, Van Ramshorst E, Van Tol A (1991) Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90:159–168PubMedCrossRef
23.
go back to reference Howard G, Sharrett AR, Heiss G et al (1993) Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 24:1297–1304PubMed Howard G, Sharrett AR, Heiss G et al (1993) Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke 24:1297–1304PubMed
24.
go back to reference Psaty BM, Furberg CD, Kuller LH et al (1992) Isolated systolic hypertension and subclinical cardiovascular disease in the elderly. Initial findings from the Cardiovascular Health Study. JAMA 268:1287–1291PubMedCrossRef Psaty BM, Furberg CD, Kuller LH et al (1992) Isolated systolic hypertension and subclinical cardiovascular disease in the elderly. Initial findings from the Cardiovascular Health Study. JAMA 268:1287–1291PubMedCrossRef
25.
go back to reference Bots ML, Hoes AW, Koudstaal PW, Hofman A, Grobbee DE (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 96:1432–1437PubMed Bots ML, Hoes AW, Koudstaal PW, Hofman A, Grobbee DE (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 96:1432–1437PubMed
26.
go back to reference O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22PubMedCrossRef O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22PubMedCrossRef
27.
go back to reference Matsumoto K, Sera Y, Nakamura H, Ueki Y, Myake S (2002) Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus. Metabolism 51:244–247PubMedCrossRef Matsumoto K, Sera Y, Nakamura H, Ueki Y, Myake S (2002) Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus. Metabolism 51:244–247PubMedCrossRef
28.
go back to reference Melidonis A, Kyriazis IA, Georgopali A et al (2003) Prognostic value of the carotid artery intima-media thickness for the presence and severity of coronary artery disease in type 2 diabetic patients. Diab Care 26:3189–3190CrossRef Melidonis A, Kyriazis IA, Georgopali A et al (2003) Prognostic value of the carotid artery intima-media thickness for the presence and severity of coronary artery disease in type 2 diabetic patients. Diab Care 26:3189–3190CrossRef
29.
go back to reference Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL (1994) Common carotid arterial wall thickness in NIDDM subjects. Diab Care 17:1330–1336CrossRef Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL (1994) Common carotid arterial wall thickness in NIDDM subjects. Diab Care 17:1330–1336CrossRef
30.
go back to reference Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M (1996) Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 27:1986–1992PubMed Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M (1996) Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 27:1986–1992PubMed
31.
go back to reference Metcalf PA, Folsom AR, Davis CE, Wu KK, Heiss G (2000) Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 47:25–35PubMedCrossRef Metcalf PA, Folsom AR, Davis CE, Wu KK, Heiss G (2000) Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 47:25–35PubMedCrossRef
32.
go back to reference Henry RM, Kostense PJ, Spijkerman AM et al (2003) Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 107:2089–2095PubMedCrossRef Henry RM, Kostense PJ, Spijkerman AM et al (2003) Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 107:2089–2095PubMedCrossRef
33.
go back to reference Zanchetti A, Crepaldi G, Bond MG et al (2001) Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. J Hypertens 19:79–88PubMedCrossRef Zanchetti A, Crepaldi G, Bond MG et al (2001) Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. J Hypertens 19:79–88PubMedCrossRef
34.
go back to reference Heiss G, Sharrett R, Barnes R, Chambless LE, Szklo M, Alzola C (1991) Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 134:250–256PubMed Heiss G, Sharrett R, Barnes R, Chambless LE, Szklo M, Alzola C (1991) Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 134:250–256PubMed
35.
go back to reference Safar ME, Levt BI, Struijker-Boudier H (2003) Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107:2864–2869PubMedCrossRef Safar ME, Levt BI, Struijker-Boudier H (2003) Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107:2864–2869PubMedCrossRef
36.
go back to reference Benetos A, Waeber B, Izzo J et al (2002) Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 15:1101–1108PubMedCrossRef Benetos A, Waeber B, Izzo J et al (2002) Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am J Hypertens 15:1101–1108PubMedCrossRef
37.
go back to reference Hodis HN, Mack WJ (1998) Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 19 [Suppl A]:A40–A44PubMed Hodis HN, Mack WJ (1998) Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 19 [Suppl A]:A40–A44PubMed
38.
go back to reference Temelkova-Kurktschiev T, Hanefeld M (2004) The lipid triad in type 2 diabetes—prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes 112:75–79PubMedCrossRef Temelkova-Kurktschiev T, Hanefeld M (2004) The lipid triad in type 2 diabetes—prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes 112:75–79PubMedCrossRef
39.
go back to reference Vakkilainen J, Jauhiainen M, Ylitalo K et al (2002) LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 43:598–603PubMed Vakkilainen J, Jauhiainen M, Ylitalo K et al (2002) LDL particle size in familial combined hyperlipidemia: effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 43:598–603PubMed
40.
go back to reference Tan KC, Shiu SW, Wong Y (2003) Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur J Clin Invest 33:301–306PubMedCrossRef Tan KC, Shiu SW, Wong Y (2003) Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur J Clin Invest 33:301–306PubMedCrossRef
41.
go back to reference Schneider M, Verges B, Klein A et al (2004) Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 53:2633–2639PubMedCrossRef Schneider M, Verges B, Klein A et al (2004) Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 53:2633–2639PubMedCrossRef
42.
go back to reference Tu AY, Albers JJ (2001) Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 50:1851–1856PubMedCrossRef Tu AY, Albers JJ (2001) Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 50:1851–1856PubMedCrossRef
43.
go back to reference Oomen PHN, Van Tol A, Hattori H, Smit AJ, Scheek LM, Dullaart RPF (2005) Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus. Diabet Med 22:768–774PubMedCrossRef Oomen PHN, Van Tol A, Hattori H, Smit AJ, Scheek LM, Dullaart RPF (2005) Human plasma phospholipid transfer protein activity is decreased by acute hyperglycaemia: studies without and with hyperinsulinaemia in Type 1 diabetes mellitus. Diabet Med 22:768–774PubMedCrossRef
Metadata
Title
Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus
Authors
R. de Vries
G. M. Dallinga-Thie
A. J. Smit
B. H. R. Wolffenbuttel
A. van Tol
R. P. F. Dullaart
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0088-0

Other articles of this Issue 2/2006

Diabetologia 2/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine